Trial Profile
A Placebo Controlled, Randomized, Double-Blind, Fixed-dose, Multicenter, Phase IIb Study to Investigate the Efficacy and Tolerability of Low Dose BAY58-2667 (25 microg/h, 10 microg/h) Given Intravenously to Subjects With Acute Decompensated Chronic Congestive Heart Failure (ADHF).
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 12 Jul 2019
Price :
$35
*
At a glance
- Drugs Cinaciguat (Primary)
- Indications Decompensated heart failure
- Focus Therapeutic Use
- Acronyms COMPOSE-2
- Sponsors Bayer; Bayer HealthCare
- 12 Jul 2019 This trial has been dicontinued in France, according to European Clinical Trials Database.
- 15 Mar 2011 Planned end date changed from 1 Jan 2012 to 1 Nov 2010 as reported by ClinicalTrials.gov.
- 15 Mar 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.